SCHEDULE: Eli Lilly Divests Entire Immunocore Holdings Stake
Beneficial Ownership Amendment
Eli Lilly and its subsidiary, Eli Lilly S.A., have reported zero beneficial ownership in Immunocore Holdings plc, indicating a complete divestment of their previous stake.
Summary
- Eli Lilly & Co and Eli Lilly S.A. have filed an Amendment No. 1 to Schedule 13G, reporting their beneficial ownership in Immunocore Holdings plc.
- Both Eli Lilly & Co and Eli Lilly S.A. now report 0.00 shares beneficially owned, representing 0.0% of Immunocore Holdings plc's Ordinary Shares.
- This filing indicates a complete divestment of their previous holdings in Immunocore Holdings plc.
- The CUSIP number for the Ordinary Shares is 54258D105.
- The date of the event which required the filing of this statement is 09/30/2025.
Sentiment
Score: 3
Explanation: The complete divestment by a major institutional investor like Eli Lilly is a significant negative signal for Immunocore Holdings plc, suggesting a lack of long-term conviction or strategic alignment.
Negatives
- The complete divestment by Eli Lilly & Co and Eli Lilly S.A. of their entire stake in Immunocore Holdings plc could be perceived negatively by the market, potentially signaling a lack of confidence or strategic misalignment from a significant institutional investor.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Immunocore Holdings plc's future performance or Eli Lilly's strategic plans beyond the divestment.
Industry Context
Eli Lilly's complete divestment from Immunocore Holdings plc could reflect a strategic portfolio re-evaluation within the pharmaceutical and biotechnology sectors, potentially indicating a shift in investment focus or a reassessment of Immunocore's long-term prospects by a major industry player.
Stakeholder Impact
- Shareholders of Immunocore Holdings plc may react negatively to the news of a major institutional investor divesting its entire stake, potentially leading to downward pressure on the stock price due to perceived loss of confidence.
Key Dates
| Date | Description |
|---|---|
| February 10, 2022 | Original power of attorney for Eli Lilly and Company and Eli Lilly S.A. filed with the SEC for the Issuer. |
| 09/30/2025 | Date of event which requires filing of this statement. |
| 10/03/2025 | Signature date for the Schedule 13G/A filing by Christopher Anderson, Attorney-in-Fact for Eli Lilly & Co and Eli Lilly S.A. |
Recommendation
sellThe complete divestment by Eli Lilly & Co and Eli Lilly S.A. of their entire stake in Immunocore Holdings plc suggests a lack of long-term conviction or a strategic re-evaluation by a significant institutional investor. This action could signal underlying concerns about Immunocore's future prospects or valuation, warranting a 'sell' recommendation for investors to re-evaluate their positions.
Keywords
Immunocore Holdings plc, Eli Lilly, Beneficial Ownership, Schedule 13G, Divestment, Ordinary Shares, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.